Introduction: Necitumumab is a monoclonal antibody targeting EGFR. In the SQUIRE trial, the addition of necitumumab to chemotherapy for squamous cell lung cancer significantly improved overall survival (OS) (hazard ratio [HR] ¼ 0.84); in a post hoc analysis, EGFR copy number gain determined by fluorescence in situ hybridization (FISH) showed a trend toward improved OS (HR ¼ 0.70) and progression-free survival (PFS) (HR ¼ 0.71) with the addition of necitumumab. We present the analysis of granular EGFR FISH data from SQUIRE to examine the potential predictive role of high polysomy and gene amplification, as both were included in the FISH-positive category.
Introduction
NSCLC is a major health care problem and accounts for a high proportion of cancer-related deaths around the world. Although cancer research has led to significant improvements in the treatment of this disease, most cases are still diagnosed at an advanced stage and the outcomes of such patients are underwhelming. 1 NSCLCs are further divided into histotypes, the most common being adenocarcinoma and squamous cell carcinoma (SCC). It is widely known that characterizing the correct histotype is pivotal for the correct treatment approach of advanced disease, as the utilization of several antineoplastic treatments and targeted agents are primariliy limited to the nonsquamous histotype. [2] [3] [4] Expression of EGFR was reported to be significantly higher in SCC than in adenocarcinoma, suggesting a potential role as a therapeutic target that has not been fully exploited yet. 5 Cetuximab, a monoclonal antibody (mAB) targeting EGFR, was used in combination with first-line chemotherapy in an open-label, phase III trial involving treatment-naive patients with advanced NSCLC in the presence of EGFR expression. 6 A retrospective but predefined analysis demonstrated an advantage in terms of overall survival (OS) in the patients whose tumor sample expressed higher levels of EGFR as assessed by immunohistochemistry (IHC), defined through a specific histoscore [H-score] ranging from 0 to 300. 7 Another subgroup analysis showed a trend toward a more pronounced survival advantage in patients with squamous histotype.
In the open-label, phase III Squamous NSCLC Treatment with the Inhibitor of EGF Receptor (SQUIRE) trial, 1093 patients with advanced squamous NSCLC were randomized to receive first-line chemotherapy based on cisplatin-gemcitabine with or without necitumumab, a human mAB directed against EGFR. The combination containing necitumumab achieved superior results in terms of OS (11.5 8 Notably, another preplanned analysis suggested that the small subgroup of patients without detectable EGFR protein by IHC, accounting for 5% of the intention-to-treat population (ITT), may not benefit from the addition of necitumumab to cisplatingemcitabine. 9 The main findings of SQUIRE have been summarized in Supplementary Table 1 .
The use of fluorescence in situ hybridization (FISH) to predict the efficacy of targeted antineoplastic treatments on the basis of gene copy number (GCN) has a relevant role in clinical practice as well as in clinical research for certain solid tumors. 10, 11 Available data suggest that EGFR GCN is associated with protein overexpression and might be correlated with survival in NSCLC. 12 Additionally, observations from S0342, a phase II trial conducted by SWOG, suggested that the outcome of patients treated with an EGFR mAB might be correlated with EGFR GCN. More specifically, of 76 patients treated with carboplatin-paclitaxel-cetuximab for advanced NSCLC, 59% were positive for increased EGFR GCN assessed through FISH and achieved an improved disease control rate (81% versus 55% [p ¼ 0.02]), PFS (6 versus 3 months [p ¼ 0.008]), and OS (15 versus 7 months [p ¼ 0.04]) compared with patients with a normal GCN. 13 A scheme for classifying NSCLC as EGFR FISH-positive or EGFR FISH-negative was developed at the University of Colorado and used in several clinical studies; these criteria, known as the Colorado scoring criteria, are based on granular parameters involving EGFR and chromosome 7 (CEP7) signals. 14, 15 The same criteria and same laboratory were used to define FISH-positive and FISH-negative patients within the large randomized SWOG 0819 study, which compared chemotherapy with carboplatin-paclitaxel (with or without bevacizumab) with or without cetuximab for advanced NSCLC; with regard to FISH status, although no difference in terms of OS was observed among patients with the nonsquamous histotype, among the 111 FISHpositive patients affected by SCC carcinoma, the addition of cetuximab to standard chemotherapy (55 patients) compared with standard chemotherapy alone (56 patients) resulted in improved OS (11.8 versus 6.4 months; HR ¼ 0.56, p ¼ 0.01). 16 In an exploratory post hoc analysis of SQUIRE, the correlation between EGFR FISH status (positive versus negative) and efficacy outcomes of 557 patients (51% of the ITT population from the SQUIRE trial) whose specimens were available for FISH analysis was assessed. Although the treatment-by-marker interaction test results were not statistically significant, a trend for a more favorable HR was observed in the FISH-positive subpopulation. Full details have been reported in Supplementary Table 2. 9 Our aim was to retrospectively explore the potential role of FISH granular data beyond the positive versus negative status as predictors of benefit from the addition of necitumumab to first-line platinum-based chemotherapy to generate hypotheses for future prospective studies.
Materials and Methods
For this study, samples collected from patients enrolled in the SQUIRE trial in agreement with study design (ClinicalTrials.gov identifier NCT00981058) 17 and considered suitable for FISH were subsequently analyzed. Of note, tissue availability was an eligibility criterion for SQUIRE, with a predefined sequence of biomarkers to be evaluated, including evaluation of EGFR GCN by FISH. The samples were fixed for 6 to 48 hours in 10% neutral buffered formalin and stored as formalinfixed, paraffin-embedded blocks; after confirmation of the presence of tumor, tissue sections measuring 3 to 5 mm were mounted on positively charged slides. Dualtarget FISH enumeration assay was performed as previously described. 15 Quality assessment for each sample and assay reading were performed by trained personnel. Five tumor areas considered representative of the tumor were selected, with each one containing an average of 10 evaluable nuclei (for a total of 50), and the number of EGFR and CEP7 signals in the selected nuclei were counted with single-pass interference filters according to published guidelines. 18 During the enumeration of the signals, doublet and triplet spots that were physically linked were counted as a single signal, whereas signals in clusters were counted to a maximum of 15 (if >15 signals, the cluster was considered innumerable and the value was reported as 16). The EGFR assay was reported as positive if at least 40% of the scored tumor cells displayed four or more copies of the EGFR signal (high polysomy) or in case of gene amplification. Gene amplification was defined as one of the following: (1) if the EGFR/CEP7 ratio was at least 2 in all scored nuclei and calculated by using the mean of EGFR signals per cell divided by the mean of CEP7 signals per cell when mean CEP7 per cell was equal to at least two copies, (2) if gene clusters (at least four spots) were present in at least 10% of neoplastic cells, or (3) if at least 15 copies of the EGFR signals were present in at least 10% of tumor cells. In all other scenarios, the results of the EGFR FISH assay were considered negative. According to the Colorado scoring criteria summarized in Table 1, 18 six categories were identified: disomy (score ¼ 1), low trisomy (score ¼ 2), high trisomy (score ¼ 3), low polysomy (score ¼ 4), high polysomy (score ¼ 5), and gene amplification (score ¼ 6). If a sample met the critieria for both high polysomy and gene amplification, the sample was categorized as having a score of 6.
Hence, the clinical data from the SQUIRE patients corresponding to the available samples, including age, sex, smoking history, Eastern Cooperative Oncology Group performance status, ethnicity, and efficacy outcomes (PFS and OS) were compared with the FISH assay results, to determine any possible correlation. Our study includes the comparison between patients with high polysomy and patients with gene amplification within the FISH positive population; additionally, the comparison included patients with at least 40% versus less than 40% of cells with four or more EGFR copies, patients with at least 10% versus less than 10% of cells with at least 15 EGFR copies, and patients with a EGFR/CEP7 ratio of at least 2 versus less than 2.
Statistical Analysis
Baseline demographic and disease characteristics between trial arms or between the subsets of patients were summarized to examine whether substantial imbalance existed. For exploratory efficacy analyses, we presented quantiles of PFS and OS within each subset and used the Cox proportional hazards model for timeto-event end points (PFS or OS). An interaction model in which an efficacy end point was modeled as a function of treatment, EGFR FISH class, and their interaction was used. HR estimates from a Cox regression model and 95% CI and log-rank p values were calculated. Because of the relatively small sample size and exploratory nature of this study, we considered only an unstratified model in all analyses without multiplicity adjustment.
Results
Among the patients enrolled in SQUIRE, 557 had tissue samples suitable for FISH analysis and provided valid results, corresponding to 51% of the ITT population. The comparative survival data for the ITT population and for the FISH analysis population are shown in Table 2 . Among the patients subjected to FISH analysis, the median PFS times in the experimental and standard arms were 5 Table 4 . With regard to FISH-positive subclassifications, all but one FISH-positive patient had at least 40% of cells with at least four EGFR copies; therefore, results for this categorization are essentially identical to FISH positivity; all but two patients with gene amplification (Colorado score of 6) had at least 10% of cells with at least 15 copies; therefore, these categorizations are essentially identical for the purpose of the analysis. The EGFR/CEP7 ratio was 2 or higher in 34 patients (6.10%) and lower than 2 in 523 patients (93.90%), respectively. Among the patients with an EGFR/CEP7 ratio of 2 or higher, the median OS times in the experimental and standard arms were 12.1 and 7. Table 3 .
When the analysis was limited to FISH-positive patients, the addition of necitumumab to chemotherapy, compared with chemotherapy alone, in patients with high polysomy (Colorado score of 5) resulted in a significant increase in terms of PFS (6.1 versus 5.1 months [p ¼ 0.044]), whereas the OS effect was not statistically significant (12.6 versus 9.5 months [p ¼ 0.133]). On the contrary, in the patients with gene amplification (Colorado score of 6), the addition of necitumumab did not improve PFS significantly (7.4 versus 5.6 months [p ¼ 0.334]) but improved OS (14.8 versus 7.6 months [p ¼ 0.033]). However, neither the OS nor the PFS interactions were significant. These results are presented in Table 4 . Analysis conclusions are limited by sample number. The Kaplan-Meier estimates for OS and PFS for this analysis are shown in Figures 1 and 2 , respectively. 
Discussion
The addition of necitumumab to first-line chemotherapy with cisplatin-gemcitabine resulted in a significant survival advantage in patients with squamous NSCLC in the randomized, phase III SQUIRE trial; to date, however, no strong predictor of benefit has been identified. Because a post hoc analysis of SQUIRE EGFR FISH status has suggested a trend toward significance in terms of outcome prediction, our hypothesis was that granular FISH data might provide potential predictive biomarkers and therefore allow identification of patients who are more likely to benefit from the addition of necitumumab. The FISH analysis population included 51% of patients from the ITT population. Within the FISH analysis population, the addition of necitumumab resulted in an improvement of PFS and OS that was numerically similar to what was observed within the ITT population; the improvements were not statistically significant within the FISH analysis population, but this observation may be related to the smaller number of patients compared to the ITT analysis. When FISH subpopulations were taken into account, the addition of necitumumab to chemotherapy resulted in an increase in OS (12.1 versus 7.6 months) among the patients harboring an EGFR/CEP7 ratio of 2 or higher; although not statistically significant, the HR for this difference was 0.63. Notably, the number of patients with increased EGFR/CEP7 ratio was limited; therefore, definitive conclusions cannot be drawn. Finally, among the FISH-positive patients, a significant advantage in terms of PFS was observed in the patients with high polysomy who were receiving chemotherapy plus necitumumab, whereas a significant advantage in terms of OS was observed in patients with gene amplification; although the interaction p values were not significant (likely because of the limited sample sizes), the HRs are not negligible, with particular mention of the HR for OS in patients with gene amplification (0.45).
There are limitations associated with this analysis, mostly deriving from the granular nature of the data. First, although a relatively large number of patients in this study had samples available for FISH analysis, the number of patients for each subcategory is limited, influencing the statistical test results; this is especially true for patients with gene amplification, who represent only 7.4% of the evaluable patients. Additionally, because this is a post hoc analysis, only a proportion (albeit generally representative) of the ITT population was eligible for this analysis and the patients had not been stratified for FISH status, potentially leading to some imbalances among demographic characteristics. Finally, although a statistically significant advantage in terms of PFS was observed in the high polysomy subcategory but not among the patients with gene amplification, it should be noted that this specific end point might be influenced by different parameters and variables, especially considering the lack of preplanned stratification for granular FISH data and the number of patients for each subcategory.
The current study of gene copy number alterations by FISH was performed in the same laboratory and with the same criteria as in the previously mentioned SWOG 0819 study comparing chemotherapy with or without cetuximab in patients with advanced NSCLC, in which EGFR FISH also seemed to predict better outcomes with the addition of cetuximab in the group of patients with SCC. 19 Thus, the potential predictive role of the EGFR FISH assay with regard to EGFR antibodies seems to be consistent in the two studies in which interlaboratory variability as a confounding factor is eliminated. Eventually, a future meta-analysis of the results from these two studies might give statistically stronger evidence regarding the predictive role of EGFR gene copy number and the FISH assay's predictive role for EGFR antibody therapy in patients with NSCLC. Additionally, further studies might allow evaluation of a greater number of patients with gene amplification, resulting in more robust data and eventually confirming the consistence of our findings.
In conclusion, although our results are not robust enough for drawing definitive conclusions with immediate clinical application, they suggest that EGFR copy number gain by FISH might have a potential role as a predictive biomarker of clinical outcomes for EGFR mABs in SCC, especially in the case of gene amplification. In consequence, we consider these data encouraging and advise the development of future studies designed to prospectively address the potential role of EGFR FISH in this setting.
